Hepatitis C virus non-structural protein 3 altered peptide ligands presented by human leukocyte antigen A*0201 (HCV NS3 APL-HLA-A*0201)

HCV NS3 altered peptide ligands (APLs) presented by HLA-A*0201 are molecular complexes targeted to enhance the immune system's ability to clear the Hepatitis C virus. The NS3 protein is essential for HCV replication, and its 1073-1081 sequence is a dominant epitope recognized by CD8+ T cells in HLA-A2+ individuals (Source: PubMed PMID: 11544324). APLs are synthetic variants of this epitope designed to modify T-cell receptor (TCR) signaling, aiming to reverse the T-cell exhaustion typically seen in chronic HCV (Source: PubMed PMID: 15141013). These ligands have been incorporated into therapeutic vaccines like IC41 to stimulate robust, virus-specific cytotoxic T lymphocyte (CTL) responses (Source: PubMed PMID: 19015124). While promising, the use of these targets must navigate the risk of viral escape through natural mutations and the potential for immune-mediated liver injury during viral clearance (Source: PubMed PMID: 12117818). This target represents a key focus in the development of personalized immunotherapies for patients with chronic HCV who do not achieve a sustained virologic response with direct-acting antivirals.

Other names

HCV NS3 1073-1081 APLNS3 peptide-HLA-A*0201 complexHLA-A2 restricted HCV NS3 epitopesHCV NS3 1073-1081 variant peptidesIC41 peptide components

Modulation of T-cell receptor (TCR) signaling through the presentation of modified viral epitopes to enhance or redirect the cellular immune response against HCV-infected hepatocytes.